Go Pro
→ Are you leaving Social Security money on the table? (From Money Pickle) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$3.90
-0.5%		$4.15
$7.96
▼
$24.15
$19.67M0.6315,685 shs17,271 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.58
+0.0%		$0.50
$0.28
▼
$2.06
$19.39M0.33210,137 shs124,443 shs
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
$3.70
-3.6%		$5.57
$3.42
▼
$154.50
$5.16M5.3629,532 shs22,526 shs
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$3.35
$3.60
$1.83
▼
$24.60
$19.35M0.9412,328 shs9,009 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.51%-4.41%-3.70%-16.31%-2.50%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
+0.02%+4.67%+26.17%-0.79%-32.03%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-3.65%-15.91%-38.84%-47.96%-97.52%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
0.00%-2.05%-2.90%+14.33%-83.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$3.90
-0.5%		$4.15
$7.96
▼
$24.15
$19.67M0.6315,685 shs17,271 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.58
+0.0%		$0.50
$0.28
▼
$2.06
$19.39M0.33210,137 shs124,443 shs
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
$3.70
-3.6%		$5.57
$3.42
▼
$154.50
$5.16M5.3629,532 shs22,526 shs
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$3.35
$3.60
$1.83
▼
$24.60
$19.35M0.9412,328 shs9,009 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.51%-4.41%-3.70%-16.31%-2.50%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
+0.02%+4.67%+26.17%-0.79%-32.03%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-3.65%-15.91%-38.84%-47.96%-97.52%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
0.00%-2.05%-2.90%+14.33%-83.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.00
Hold$3.00416.88% Upside
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
1.00
SellN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
2.00
Hold$23.00586.57% Upside

Current Analyst Ratings Breakdown

Latest LIMN, NCEL, ALVR, and KTTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/13/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/13/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$23.00
6/29/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
6/24/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/16/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$1.49 per shareN/A
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/A$0.22 per shareN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/A$1.59 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$20.43M-$1.58N/AN/AN/AN/A-49.49%-46.81%11/12/2026 (Estimated)
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-$10.21M-$23.50N/AN/AN/AN/AN/A-256.58%N/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
-$8.30MN/AN/AN/AN/AN/AN/AN/AN/A

Latest LIMN, NCEL, ALVR, and KTTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$0.16-$0.16N/A-$0.16$0.30 millionN/A
8/14/2026Q2 2026
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A-$1.50N/A-$0.03N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
26.25
26.25
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A
1.12
1.12
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
1.50%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
19.40%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
16.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
333.41 million32.91 millionNot Optionable
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A1.34 million1.08 millionN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
65.78 million4.83 millionNot Optionable

Recent News About These Companies

Der aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.
August 27, 2026  |  de.investing.comhttps://de.investing.com/equities/nls-pharmaceutics-ag
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336827/0/en/newcelx-announces-pricing-of-1-4-million-equity-financing-at-20-premium-pricing.html
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324174/0/en/newcelx-appoints-world-renowned-diabetes-cure-focused-pioneer-dr-camillo-ricordi-to-scientific-advisory-board.html
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320694/0/en/newcelx-announces-successful-fda-pre-ind-meeting-with-clear-path-forward-for-ncel-101-toward-starting-clinical-trials-for-type-1-diabetes.html
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311778/0/en/newcelx-publishes-peer-reviewed-study-demonstrating-broad-therapeutic-potential-of-its-stem-cell-technology-platform.html
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
May 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/27/3301840/0/en/newcelx-ltd-submits-pre-ind-package-to-the-fda-for-ncel-101-for-the-treatment-of-type-1-diabetes.html
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284829/0/en/newcelx-reports-financial-results-for-2025-and-provides-shareholders-with-update-on-accelerated-development-of-type-1-diabetes-treatment-in-collaboration-with-eledon-pharmaceutical.html
Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock
April 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ncel-insider-buying-and-selling-2026-04-30/
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276901/0/en/newcelx-updates-corporate-presentation-to-highlight-type-1-diabetes-flagship-program-following-strategic-collaboration-with-eledon-pharmaceuticals-ahead-of-swiss-biotech-conference.html
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
April 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/01/3266497/0/en/newcelx-announces-pricing-of-1-35-million-equity-financing-at-30-premium-pricing.html
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
March 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes-302708071.html
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
February 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-reports-peer-reviewed-publication-supporting-mazindol-irsr-and-advances-cvr-monetization-strategy-302686180.html
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
January 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announces-updated-corporate-presentation-ahead-of-key-spring-2026-investor-and-partnering-conferences-302673887.html
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
January 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announce-positive-results-from-international-collaborative-study-exploring-advanced-biomaterial-approaches-for-stem-cellderived-islet-delivery-in-type-1-diabetes-without-immune-suppression-302658361.html
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
January 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-appoints-dr-julien-boisdron-a-swiss-big-pharma-leader-in-diabetes-innovation-to-its-scientific-advisory-board-302652531.html
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
December 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-expands-intellectual-property-footprint-with-publication-of-doxa-patent-application-in-china-302638937.html
NewCelX Appoints EY as New Auditor Following Merger
November 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newcelx-appoints-ey-as-new-auditor-following-merger?utm_source=marketbeat.com&utm_medium=referral
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
November 17, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-strengthens-scientific-advisory-board-with-appointment-of-jeremy-shefner-md-phd-chief-medical-officer-at-the-barrow-neurological-institute-302616848.html
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
November 6, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announces-scientific-leadership-with-the-head-of-division-of-medical-neurosciences-at-the-department-of-neurology-at-hadassah-prof-tamir-ben-hur-on-its-scientific-advisory-board-302606998.html
NewcelX Ltd.
November 5, 2025  |  cnn.comhttps://www.cnn.com/markets/stocks/NCEL

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
SK Hynix logo displayed on a semiconductor wafer, with memory chip modules visible in the background.
SK hynix Triggers $28B Defense Against Tech Selloff
By Jeffrey Neal Johnson | August 21, 2026
AlloVir stock logo

AlloVir NASDAQ:ALVR

$3.90 -0.02 (-0.51%)
As of 09/2/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.58 +0.00 (+0.02%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.59 +0.01 (+1.31%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Liminatus Pharma stock logo

Liminatus Pharma NASDAQ:LIMN

$3.70 -0.14 (-3.65%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$3.84 +0.15 (+3.92%)
As of 07:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NCEL

$3.35 0.00 (0.00%)
As of 09/3/2026 03:51 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas